| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 62.33 |
| Santhera Pharmaceuticals Holding AG | 15.86 |
| Catalyst Pharmaceuticals, Inc. | 11.21 |
| Idorsia Ltd. | 10.31 |
| UBS (CH) Instl. Fund - Equities Switzerland Passive All II | 1.03 |
| UBS (CH) Investment Fund - Equities Switzerland Passive All | 0.99 |
| UBS (CH) Instl. Fund - Eq. Switzerland Small & Mid Pass. II | 0.93 |
| UBS (Lux) Bond Fund - Convert Europe (EUR) | 0.76 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 119 | 117 | 91 | 43 | 51 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.27 | 0.64 | 0.16 | -0.04 | 0.15 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 43 | 49 | 18 | 25 | 3 |
| Summe Anlagevermögen | 82 | 81 | 65 | 51 | 8 |
| Summe Aktiva | 110 | 115 | 89 | 91 | 64 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 55 | 60 | 71 | 49 | 52 |
| Summe Fremdkapital | 82 | 94 | 95 | 90 | 107 |
| Summe Eigenkapital | 28 | 21 | -6 | 1 | -44 |
| Summe Passiva | 110 | 115 | 89 | 91 | 64 |
Adresse
| Hohenrainstrasse 24, 4133 Pratteln | |
| Telefon | +41 (61) 906-89-50 |
| Fax | +41 (61) 906-89-51 |
| URL | http://www.santhera.com |
Management
|
Andreas Missy
Chief of Staff |
|
Andrew P. Smith
Chief Financial Officer |
|
Bradley Carl Meyer
Director |
|
Dario Eklund
Chief Executive Officer |
|
Günther Metz
Executive VP & Head-Business Development |
|
Marc Schrader
Head-Technical Development & Operations |
|
Neville Kodkani
Head-Global Marketing & Partner Management |
|
Oliver Strub
Secretary, Executive VP & General Counsel |
|
Otto Schwarz
Director |
|
Philipp Gutzwiller
Independent Director |
|
Sarah Holmes-Klotz
Global Head-People & Culture |
|
Shabir Hasham
Chief Medical Officer |
|
Stephanie Brown
President-North America |
|
Thomas Meier
Chairman |